The TP63 antibody targets proteins encoded by the *TP63* gene, a member of the p53 tumor suppressor family. TP63 produces multiple isoforms through alternative splicing, primarily classified into two groups: TAp63 (transactivation-competent) and ΔNp63 (N-terminal truncated). These isoforms play distinct roles in epithelial development, cell differentiation, and oncogenesis. ΔNp63. the predominant isoform in stratified epithelia, acts as a survival factor and maintains stem cell populations, while TAp63 regulates apoptosis and senescence. TP63 is highly expressed in basal cells of epithelial tissues and is implicated in squamous cell carcinomas (SCCs), where ΔNp63 overexpression drives tumor progression.
Antibodies against TP63 are vital tools in research and diagnostics. They help identify cell origins in developmental studies, assess epithelial malignancies (e.g., lung, head/neck, and bladder cancers), and distinguish SCCs from other carcinomas. Commonly used clones like 4A4 detect all TP63 isoforms, while p40 (ΔNp63-specific) improves diagnostic specificity for SCCs. In immunohistochemistry, TP63 antibodies aid in classifying poorly differentiated tumors and evaluating metastatic origins. However, interpretation requires caution, as expression varies by tissue context and isoform functionality. Researchers also utilize these antibodies to explore TP63's role in stem cell regulation, tissue regeneration, and response to therapies. Their utility underscores TP63's dual role as both an oncogene and a guardian of epithelial integrity.